INMB INmune Bio Inc.
$1.41▼ -1.40%
Healthcare
Other
Volume 25.8K
Avg Volume (10D) 324.0K
Key Metrics & Fundamentals
Market Cap
$39.13M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.09 - 2.60
% vs 50 MA
-30.08%
% vs 200 MA
-12.63%
RSI-14
27.3
MACD Histogram
-0.0200
Beta (1Y vs SPY)
2.53
Free Cash Flow
-$3.61M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.41M
COGS
–
Operating Exp
$1.48M
Operating Income
-$1.48M
EBIT
-$1.48M
Pretax Income
-$1.27M
Net Income
-$1.27M
EPS (Diluted)
-0.05
Price & Volume History
Loading chart…
Recent News
Manufacturing Progress Gives INmune Bio a Clearer UK Filing Path for Ebstrocel
InvestorsHub · Oct 21, 2026 2:28 PM ET
INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027
GlobeNewswire · Oct 21, 2026 7:15 AM ET
INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar
GlobeNewswire · Oct 21, 2026 7:00 AM ET
Can Quantum Computing (QUBT) Be A Bargain As Its INmune Bio Deal Opens Biopharma?
Simply Wall St. · Oct 16, 2026 12:30 AM ET
QCi and INmune Bio partner to study XPro in Alzheimer’s
Pharmaceutical Technology · Oct 15, 2026 6:59 AM ET
INmune Bio, Quantum Computing Team Up to Identify New Uses for Alzheimer's Drug
MT Newswires · Oct 14, 2026 9:15 AM ET
INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™
GlobeNewswire · Oct 14, 2026 8:45 AM ET
INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™
PR Newswire · Oct 14, 2026 8:30 AM ET
INmune Bio to Attend the 2026 Maxim Growth Summit
GlobeNewswire · Oct 6, 2026 9:00 AM ET
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
GlobeNewswire · Sep 14, 2026 7:00 AM ET
Financial Overview - Income Statement
Quarterly
Mar 2025
See INMB's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.